| Predicate |
Object |
| contentType |
Editorial|Comment |
| endingPage |
S392 |
| issn |
2226-4477
2218-6751 |
| issueIdentifier |
Suppl 4 |
| pageRange |
S388-S392 |
| publicationName |
Translational Lung Cancer Research |
| startingPage |
S388 |
| bibliographicCitation |
Arulananda S, Mitchell P. Elderly patients with stage III NSCLC survive longer when chemotherapy is added to radiotherapy-fortune favours the bold. Transl Lung Cancer Res. 2018 Dec;7(Suppl 4):S388–92. PMID: 30705864; PMCID: PMC6328698. |
| creator |
http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0002-5636-6381
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_4fde6e200f450d18e4273ccef2b7a684
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_79f8434d2f4b59980ce0b4882c1b9145 |
| date |
201812 |
| identifier |
https://pubmed.ncbi.nlm.nih.gov/PMC6328698
https://pubmed.ncbi.nlm.nih.gov/30705864
https://doi.org/10.21037/tlcr.2018.08.12 |
| isPartOf |
https://portal.issn.org/resource/ISSN/2226-4477
http://rdf.ncbi.nlm.nih.gov/pubchem/journal/43494
https://portal.issn.org/resource/ISSN/2218-6751 |
| language |
English |
| source |
https://www.crossref.org/
https://pubmed.ncbi.nlm.nih.gov/ |
| title |
Elderly patients with stage III NSCLC survive longer when chemotherapy is added to radiotherapy—fortune favours the bold |